ReviewCurrent hematologic malignancy reports2019
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Sarah A Holstein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled ittrialcites it